Abstract
RAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines. ZHX2 was weakly expressed in high-risk/proliferative disease compared to low-risk or indolent disease. High ZHX2 expression was associated with better response and longer survival after high-dose therapy. RCBTB2 expression was weaker in hyperdiploid versus non-hyperdiploid cases while RAN was more expressed in symptomatic MM and cell lines.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Age Factors
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / genetics
-
Biomarkers, Tumor / metabolism*
-
Bone Marrow Cells / metabolism
-
Female
-
Gene Expression
-
Gene Expression Profiling / methods
-
Homeodomain Proteins / genetics
-
Homeodomain Proteins / metabolism*
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / metabolism*
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / metabolism*
-
Paraproteinemias / drug therapy
-
Paraproteinemias / metabolism
-
Plasma Cells / metabolism
-
Prognosis
-
Reverse Transcriptase Polymerase Chain Reaction / methods
-
Transcription Factors / genetics
-
Transcription Factors / metabolism*
-
Treatment Outcome
-
ran GTP-Binding Protein / genetics
-
ran GTP-Binding Protein / metabolism
Substances
-
Biomarkers, Tumor
-
Homeodomain Proteins
-
Neoplasm Proteins
-
RAN protein, human
-
RCBTB2 protein, human
-
Transcription Factors
-
ZHX2 protein, human
-
ran GTP-Binding Protein